Codiak Biosciences Inc

NASDAQ:CDAK   10:31:42 AM EDT
14.53
+0.58 (+4.16%)
Products

Codiak Reports Positive Initial Data From Phase 1/2 Trial Of Exosting™ Indicating Evidence Of Tumor Shrinkage

Published: 11/16/2021 12:06 GMT
Codiak Biosciences Inc (CDAK) - Codiak Reports Positive Initial Data for Exosting™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-injected Tumors in First Three Dose Escalation Cohorts.
Codiak Biosciences, Inc. - Data on Objective Response Rate and Recommended Phase 2 Dose Selection for Expansion Anticipated 1h 2022.
Codiak Biosciences Inc - Within First Three Dose Cohorts, Exosting Was Generally Well Tolerated and No Treatment-related Adverse Events Were Observed.
Codiak Biosciences, Inc. - Enrollment in Cohorts 4 (6 Mcg) and 5 (12 Mcg) of Exosting Trial is Ongoing.